Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (10) : 929-933     DOI: 10.3971/j.issn.1000-8578.2021.21.0261
|
Experiment on Inhibiting NEK7 to Promote Apoptosis of Hepatocellular Carcinoma Cells
SONG Yanzhou1, ZHANG Kun1, CHEN Qijun1, WEI Wenping1, ZHAO Xin1, LI Zhiwei1, LI Wei2
1. Department of Hepatobiliary Surgery, The Third People’s Hospital of Shenzhen (The Second Af filiated Hospital of Southern University of Science and Technology), Shenzhen 518000, China; 2. Department of Hepatobiliary Surgery, The First People’s Hospital of Lianyungang (The Af filiated Lianyungang Hospital of Xuzhou Medical University), Lianyungang 222000, China
Download: PDF(6930 KB)   ( 68 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To use in vitro experiments to verify the changes of proliferation, senescence and apoptosis of hepatocellular carcinoma cells after inhibiting the expression of NEK7, and to explore the related molecular mechanism. Methods Western blot and RT-PCR were used to detect the expression of NEK7 in hepatocellular carcinoma cells and THLE-2 cells. A viral vector was designed to inhibit the expression of NEK7 based on the gene sequence. After hepatocellular carcinoma cells were transfected, we observed the changes of proliferation activity, cell senescence, cell apoptosis and cell cycle in vitro. Western blot was used to detect the expression of cell cycle-related factors. Results Compared with THLE-2 cells, NEK7 was highly expressed in hepatocellular carcinoma cells. After inhibiting the expression of NEK7 with shRNA, the proliferation of hepatocellular carcinoma cells was inhibited, the proportions of cell senescence and apoptosis were increased, meanwhile, the cell number in stage S and G2/M was significantly reduced, the cell cycle progression was blocked, the expression levels of C-myc, c-Fos, cyclin D1 and cyclin E were inhibited, P16 and P27 expression were increased, and CDK2, CDK4 and CDK6 expression were not significantly changed. Conclusion After inhibiting the expression of NEK7, the proliferation ability of hepatocellular carcinoma cells is reduced, cell senescence is promoted and apoptosis is induced; meanwhile, the cell cycle progress is blocked.
Keywords Hepatocellular carcinoma      NEK7      Cell cycle     
ZTFLH:  R735.7  
Fund:The Fifth Phase of “521 Project” Scientific Research Project in Lianyungang (No. LYG52105-2018074)
Issue Date: 15 October 2021
 Cite this article:   
SONG Yanzhou,ZHANG Kun,CHEN Qijun, et al. Experiment on Inhibiting NEK7 to Promote Apoptosis of Hepatocellular Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 929-933.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0261
http://www.zlfzyj.com/EN/Y2021/V48/I10/929
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
SONG Yanzhou
ZHANG Kun
CHEN Qijun
WEI Wenping
ZHAO Xin
LI Zhiwei
LI Wei
[1] Goshima G, Wollman R, Goodwin SS, et al. Genes required for
mitotic spindle assembly in Drosophila S2 cells[J]. Science, 2007,
316(5823): 417-421.
[2] Gupta A, Tsuchiya Y, Ohta M, et al. NEK7 is required for G1
progression and procentriole formation[J]. Mol Biol Cell, 2017,
28(15): 2123-2134.
[3] Kim S, Lee K, Rhee K. NEK7 is a centrosomal kinase critical for
microtubule nucleation[J]. Biochem Biophys Res Commun, 2007,
360(1): 56-62.
[4] Wang R, Song Y, Xu X, et al. The expr‍ession of Nek7, FoxM1,
and Plk1 in gallbladder cancer and their relationships to
clinicopathologic features and survival[J]. Clin Transl Oncol,
2013, 15(8): 626-632.
[5] Fry AM, O′Regan L, Sabir SR, et al. Cell cycle regulation by
the NEK family of protein kinases[J]. J Cell Sci, 2012, 125(Pt
19): 4423-4433.
[6] Tan R, Nakajima S, Wang Q, et al. Nek7 Protects Telomeres from
Oxidative DNA Damage by Phosphorylation and Stabilization of
TRF1[J]. Mol Cell, 2017, 65(5): 818-831.
[7] Eisa NH, Jilani Y, Kainth K, et al. The co-chaperone UNC45A
is essential for the expr‍ession of mitotic kinase NEK7 and
tumorigenesis[J]. J Biol Chem, 2019, 294(14): 5246-5260.
[8] Romagosa C, Simonetti S, López-Vicente L, et al. p16(Ink4a)
overexpr‍ession in cancer: a tumor suppressor gene associated with
senescence and high-grade tumors[J]. Oncogene, 2011, 30(18):
2087-2097.
[9] Razavipour SF, Harikumar KB, Slingerland JM. p27 as a
Transcriptional Regulator: New Roles in Development and
Cancer[J]. Cancer Res, 2020, 80(17): 3451-3458.
[10] García-Gutiérrez L, Delgado MD, León J. MYC Oncogene
Contributions to Release of Cell Cycle Brakes[J]. Genes(Basel),
2019, 10(3): 244.
[11] Tsiambas E, Mastronikolis N, P Fotiades P, et al. c-Jun/c-Fos
complex in laryngeal squamous cell carcinoma[J]. J BUON, 2020,
25(2): 618-620.
Related articles from Frontiers Journals
[1] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[2] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[3] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[4] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
[5] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[6] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[7] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[8] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[9] CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 438-443.
[10] WANG Yueqin, FENG Luyao, TIAN Xin. Mechanism of HSP90 Inhibitor AUY-922 Reversing ALK Inhibitor Resistance in Human Neuroblastoma Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 294-298.
[11] ZHOU Yongjie, WANG Zhengfeng, YAN Jun, WANG Haiping, XU Wen, ZHOU Wence. Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 347-351.
[12] TAO Changcheng, ZHANG Kai, RONG Weiqi, WU Jianxiong. Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 359-363.
[13] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[14] CHEN Long, LIU Yujie, TIAN Suqing, WANG Cuiying, HE Donglei. Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 53-57.
[15] PANG Kangqing, MA Hongde, YANG Rulei, PANG Guohong. Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1078-1081.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed